Thomas Michael Thestrup, formerly director for corporate business development and strategy for Denmark-listed pharmaceutical group Lundbeck, has joined Italy-based peer Angelini Pharma’s corporate venturing department as investment director.
Thestrup said: I will be working with Angelini’s R&D [research and development] external innovation team, Lumira Ventures and our joint Angelini Lumira Biosciences Fund and ArgoBio Studio.
“Looking forward to an exciting adventure investing in innovative and novel sciences and building companies that can help people with [central nervous system] and rare diseases.”
Prior to joining Lundbeck in 2019, Thestrup had been associate director of global business development for another drug producer, UCB, since 2017. He had previously been an associate at venture capital firm Sunstone Life Science Ventures for about two years until late 2017.
Photo of Thomas Michael Thestrup courtesy of LinkedIn.
